Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab in combination therapy for triple-negative breast cancer
NCT04958785Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Dec 2021
- Primary completion
- Oct 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of magrolimab in triple-negative breast cancer (TNBC) (5 cohorts), sponsored by Gilead Sciences. Primary endpoints: Dose-Limiting Toxicities at 21 days, Treatment-emergent Adverse Events at 73 weeks and 3 more. Started Dec 2021; status: terminated.
02
Drugs
magrolimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04958785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04958785.